trending Market Intelligence /marketintelligence/en/news-insights/trending/nX_24498_lIqHG7h7bqzuA2 content esgSubNav
In This List

Momenta Pharmaceuticals to raise up to $230M from common stock offering

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Momenta Pharmaceuticals to raise up to $230M from common stock offering

Momenta Pharmaceuticals Inc. priced an underwritten public offering of its common stock to raise up to $230 million in gross proceeds.

The Cambridge, Mass.-based biotechnology company is offering $200 million worth of its shares. Underwriters will also receive an option to buy up to an additional $30 million of the company's common stock.

Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering, while Stifel is acting as a book-running manager.